Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

Project Progress - The company announced the completion of the "Marketing Network Center Construction Project" and the "Hangzhou Aokai Biological Annual Production of 400 Million In Vitro Diagnostic Reagents R&D Center Construction Project," resulting in approximately 210 million yuan of surplus raised funds to permanently supplement working capital, optimizing fund efficiency [2] Fund Movements - On January 21, 2026, the company's board approved a share repurchase plan, intending to use 100 to 200 million yuan of over-raised funds for a buyback at a price not exceeding 85 yuan per share, aimed at reducing registered capital. This plan was approved at the extraordinary shareholders' meeting on February 6, 2026, and will be executed within the next 12 months [3] Strategic Advancement - The announcement also disclosed the 2026 annual routine related party transaction plan, totaling 51.3 million yuan, focusing on high-margin areas such as respiratory multiplex testing and pet diagnostics to address industry transformation [4]

Core Viewpoint - The company plans to repurchase its shares using funds raised from its initial public offering, with the aim of reducing its registered capital and enhancing shareholder value [2][36]. Group 1: Share Repurchase Details - The total amount for the share repurchase will be no less than RMB 100 million and no more than RMB 200 million [2]. - The repurchase price will not exceed RMB 85 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [2][14]. - The repurchase will be conducted through centralized bidding [3][9]. Group 2: Implementation Timeline - The repurchase period will last for 12 months from the date the shareholders' meeting approves the plan [4][10]. - If the repurchase amount reaches the upper limit, the plan will be completed early [11]. Group 3: Purpose and Funding - The purpose of the repurchase is to maintain shareholder interests and enhance investor confidence based on the company's future development prospects [7][36]. - The funds for the repurchase will come from the excess funds raised during the company's initial public offering [15][36]. Group 4: Shareholder and Management Plans - As of the announcement date, there are no plans for share reductions by directors, senior management, or major shareholders in the next three to six months [4][18]. - The proposal for the share repurchase was initiated by the company's controlling shareholder and chairman, Gao Fei [19][36]. Group 5: Legal and Regulatory Compliance - The company has complied with relevant laws and regulations regarding the share repurchase process, including notifying creditors as required [7][37]. - The repurchased shares will be legally canceled, thereby reducing the registered capital [20][21].

证券代码：688606 证券简称：奥泰生物 公告编号：2026-009 杭州奥泰生物技术股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2026 年 2 月 6 日 （二） 股东会召开的地点：浙江省杭州市钱塘区下沙街道乔新路 383 号公司会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 88 | | --- | --- | | 普通股股东人数 | 88 | | 2、出席会议的股东所持有的表决权数量 | 56,664,002 | | 普通股股东所持有表决权数量 | 56,664,002 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 72.0107 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 72.0107 | 注：截 ...

二、需债权人知晓的相关信息 根据《中华人民共和国公司法》（以下简称"《公司法》"）等相关法律、 法规的规定，公司债权人自接到公司通知之日起 30 日内，未接到通知者自本公 告披露之日起 45 日内，均有权凭有效债权文件及相关凭证要求公司清偿债务或 者提供相应担保。债权人如逾期未向公司申报债权，不会因此影响其债权的有效 性，相关债务（义务）将由公司根据原债权文件的约定继续履行，本次回购注销 将按法定程序继续实施。公司债权人如要求公司清偿债务或提供相应担保的，应 根据《公司法》等相关法律、法规的规定向公司提出书面要求，并随附有关证明 文件。 （一）债权申报所需材料 证券代码：688606 证券简称：奥泰生物 公告编号：2026-010 杭州奥泰生物技术股份有限公司 关于回购股份用于注销并减少注册资本暨通知债权 人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、通知债权人的原因 杭州奥泰生物技术股份有限公司（以下简称"公司"）于 2026 年 1 月 21 日、2026 年 2 月 6 日分别召开第三届董事会第十九次会议 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2026-011 杭州奥泰生物技术股份有限公司 关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含）。 ● 回购股份资金来源：杭州奥泰生物技术股份有限公司（以下简称"公司"） 首次公开发行股票超募资金。 ● 回购股份用途：用于减少注册资本。 ● 回购股份价格：不超过人民币 85 元/股（含）；不超过董事会通过回购股 份决议前 30 个交易日公司股票交易均价的 150%。 ● 回购股份方式：以集中竞价交易方式。 4、本次回购的股份将依法注销并减少注册资本，可能存在公司债权人要求公 司提前清偿债务或者提供相应担保的风险； 5、如遇监管部门颁布新的回购相关规范性文件，导致本次回购实施过程中需 要根据监管新规调整回购相应条款的风险。 公司将努力推进本次回购方案的顺利实施，在回购期限内根据市场情况择机 做出回购决策并予以实施，并根 ...

礼丰律师事务所 关于杭州奥泰生物技术股份有限公司 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定及法律意 见书出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽 责和诚实信用原则，进行了充分的核查验证，保证法律意见所认定的事实真实、 准确、完整、及时，所发表的结论性意见合法、准确，不存在虚假记载、误导性 陈述或者重大遗漏，并承担相应法律责任。 本所律师已经按照有关法律法规的要求和律师行业公认的道德标准以及勤 勉尽责的精神对公司本次股东会相关文件及事实进行了审查和验证。 在进行审查验证过程中，本所假设： 1 1. 上述文件中的所有签署、盖章及印章都是真实的，所有作为正本提交给 本所的文件都是真实、准确、完整的； 2. 上述文件中所述的全部事实都是真实、准确、完整的； 3. 上述文件的签署人均具有完全的民事行为能力，并且其签署行为已获得 恰当、有效的授权； 2026 年第一次临时股东会的法律意见书 致：杭州奥泰生物技术股份有限公司 上海礼丰律师事务所(以下简称"本所")接受杭州奥泰生物技术股份有限公司 (以下简称 ...

Group 1 - The company announced that its controlling shareholder, actual controller, and chairman Gao Fei proposed a share buyback through centralized bidding, which has been approved by the shareholders' meeting [1] - The buyback amount will not be less than 100 million yuan and not exceed 200 million yuan, with a price not exceeding 85 yuan per share, expecting to repurchase between 1.1765 million and 2.3529 million shares, accounting for 1.48%-2.97% of the total share capital [1] - The funds for the buyback will come from the excess funds raised from the initial public offering, aimed at reducing registered capital [1] Group 2 - The buyback period will last for 12 months from the date of approval by the shareholders' meeting, and relevant personnel have no plans to reduce their holdings in the next 3 to 6 months [1] - There are risks associated with price changes and plan modifications regarding the buyback [1]

注1：以上持股数比例若有差异，系百分比结果四舍五入所致。 注2：公司股份全部为无限售条件流通股，因此公司的前十名股东持股情况 和前十名无限售条件股东持股情况一致。 证券代码：688606 证券简称：奥泰生物 公告编号：2026-008 杭州奥泰生物技术股份有限公司 关于回购股份事项前十名股东和前十名无限售条件 股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州奥泰生物技术股份有限公司（以下简称"公司"）于2026年1月21日召 开第三届董事会第十九次会议，审议通过《关于<以集中竞价交易方式回购公司 股份方案>的议案》。具体内容详见公司于2026年1月22日在上海证券交易所网 站（www.sse.com.cn）披露的《关于以集中竞价交易方式回购股份的预案》 （公告编号：2026-004）、《关于召开2026年第一次临时股东会的通知》（公 告编号：2026-006）。 根据《上海证券交易所上市公司自律监管指引第7号——回购股份》等相关 规定，现将公司2026年第一次临时股东会的股权登记日（即2026年2月 ...

Core Viewpoint - The company, Hangzhou Aotai Biological Technology Co., Ltd., has announced the details regarding the share repurchase plan and the shareholding status of its top ten shareholders and top ten unrestricted shareholders as of January 21, 2026 [1][2]. Group 1 - The company's board of directors approved the share repurchase plan during the 19th meeting of the third board on January 21, 2026 [1]. - The details of the share repurchase plan were disclosed on January 22, 2026, on the Shanghai Stock Exchange website [1]. - The announcement includes the names, shareholding quantities, and shareholding ratios of the top ten shareholders and top ten unrestricted shareholders as of the day before the board meeting [1]. Group 2 - All shares of the company are unrestricted circulating shares, meaning the shareholding situation for the top ten shareholders and the top ten unrestricted shareholders is identical [2]. - The company ensures that the announcement contains no false records, misleading statements, or significant omissions, and the board takes legal responsibility for the content's authenticity, accuracy, and completeness [1].